Literature DB >> 17046239

An immunohistochemical study of p16(INK4a) expression in multistep thyroid tumourigenesis.

Elizabeth Ball1, Jane Bond, Brigitte Franc, Catherine Demicco, David Wynford-Thomas.   

Abstract

Normal human thyroid follicular epithelial cells exhibit a very low proliferative rate which in vitro is dramatically increased by RAS oncogene activation, resulting in clones displaying a phenotype consistent with that of a ras-induced follicular adenoma in vivo. Eventual spontaneous cessation of growth of these clones is closely correlated with increasing expression of the tumour suppressor gene p16(INK4a), suggesting that p16 may limit clonal expansion in this tumour model. We therefore hypothesised that p16 expression would also increase in vivo in follicular adenomas, and further that escape from growth control in follicular cancers would be accompanied by loss of p16 expression. This was tested using tissue microarrays, representing multiple stages of thyroid tumourigenesis. Whereas the majority of normal thyroids showed no immunostaining, p16 protein was readily detectable in follicular adenomas. Unexpectedly, however, p16 expression was also observed in follicular and papillary carcinomas. Poorly differentiated (insular) carcinomas showed either very intense staining, or a complete loss of staining. We conclude that loss of p16 is not necessary for malignant transformation in thyroid follicular cells, but that it may form one of two or more events needed for progression to more aggressive forms of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046239     DOI: 10.1016/j.ejca.2006.08.025

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma.

Authors:  Sung-Im Do; Dong Hyun Kim; Jung-Ho Yang; Jung-Soo Pyo; Kyungeun Kim; Hyunjoo Lee; In-Gu Do; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn
Journal:  Tumour Biol       Date:  2015-10-07

2.  Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.

Authors:  Michael J Demeure; Meraj Aziz; Richard Rosenberg; Steven D Gurley; Kimberly J Bussey; John D Carpten
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

3.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

4.  Expression of p21cip1, p27kip1, and p16INk4a cyclin-dependent kinase inhibitors in papillary thyroid carcinoma: correlation with clinicopathological factors.

Authors:  Carles Zafon; Gabriel Obiols; Josep Castellví; Santiago Ramon y Cajal; Juan Antonio Baena; Jordi Mesa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

5.  Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients.

Authors:  Anna Felisiak-Golabek; Alina Rembiszewska; Iwona K Rzepecka; Lukasz Szafron; Radoslaw Madry; Magdalena Murawska; Tomasz Napiorkowski; Piotr Sobiczewski; Beata Osuch; Jolanta Kupryjanczyk
Journal:  J Ovarian Res       Date:  2011-11-10       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.